Design Therapeutics (DSGN) EBITDA Margin (2020)

Design Therapeutics (DSGN) posted quarterly EBITDA Margin of 11700.0% for Q4 2020, up 1.8% on a QoQ basis from 11915.0% in Q3 2020.

Design Therapeutics (DSGN) EBITDA Margin (2020) Analysis & Trends

Design Therapeutics has reported EBITDA Margin for 1 years, with the latest figure at 11700.0% in Q4 2020.

EBITDA Margin for Q4 2020 came in at 11700.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was 3685.84% (changed N/A YoY), and the FY2020 annual result was 3685.84%, changed N/A from the prior year.
EBITDA Margin grew to 11700.0% in Q4 2020, from 11915.0% in the prior quarter.
Over five years, EBITDA Margin peaked at 438.73% in Q1 2020 and troughed at 11915.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Design Therapeutics	928.06 Mn	720.67 Mn	-	-

Download Data